Home Business Sanofi still in red in Paris, weighs news of experimental drug development interruption

Sanofi still in red in Paris, weighs news of experimental drug development interruption

by admin

Sanofi’s bad day on the Paris Stock Exchange continues, where the stock of the French big pharma fell by almost 4%. The announcement of the discontinuation of the worldwide clinical development program of amcenestrant, an experimental cure for some types of breast cancer, weighed on the title. In an official note, Sanofi announced that “it has completed the global clinical development program of amcenestrant, a selective estrogen receptor degrader for oral intake based on some phase 3 studies Ameera-5 evaluating the drug in combination with palbociclib , compared with letrozole in combination with palbociclib in patients with advanced breast cancer “. “The company will continue to review the data and aim to share the results with the scientific community in the future,” the note concludes.

See also  The Italian Sea Group: sent to Deloitte for analysis of Perini Navi documentation

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy